Abstract
Inhibition of Leishmania infantum trypanothione disulfide reductase (LiTryR) by disruption of its homodimeric interface has proved to be an alternative and unexploited strategy in the search for novel antileishmanial agents. Proof of concept was first obtained by peptides and peptidomimetics. Building on previously reported dimerization disruptors containing an imidazole-phenyl-thiazole scaffold, we now report a new 1,2,3-triazole-based chemotype that yields noncompetitive, slow-binding inhibitors of LiTryR. Several compounds bearing (poly)aromatic substituents dramatically improve the ability to disrupt LiTryR dimerization relative to reference imidazoles. Molecular modeling studies identified an almost unexplored hydrophobic region at the interfacial domain as the putative binding site for these compounds. A subsequent structure-based design led to a symmetrical triazole analogue that displayed even more potent inhibitory activity over LiTryR and enhanced leishmanicidal activity. Remarkably, several of these novel triazole-bearing compounds were able to kill both extracellular and intracellular parasites in cell cultures.
Highlights
Leishmaniasis is an infectious disease caused by intracellular protozoan parasites from more than 20 Leishmania species and transmitted to humans through the bite of infected female phlebotomine sandflies
The development of new and more efficient antileishmanial drugs is a priority in the field of neglected tropical diseases
From a small library of 26 triazole-phenyl-thiazole compounds, we have identified the most potent small-molecule dimerization disruptors of Leishmania infantum trypanothione disulfide reductase (LiTryR) described to date
Summary
Leishmaniasis is an infectious disease caused by intracellular protozoan parasites from more than 20 Leishmania species and transmitted to humans through the bite of infected female phlebotomine sandflies. VL is caused by Leishmania donovani and Leishmania infantum parasites worldwide, including Mediterranean countries.[2] No effective vaccine for humans has so far been developed, and leishmaniasis control mainly relies on chemotherapy.[3,4] currently available treatments are inadequate because of high costs, toxicity, drug resistance, and the need for parenteral administration.[5,6] there is an urgent need to find new effective innovative drugs against this disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.